TickerFacts.

Profound Medical Corp. (PROF): R&D Expense

Annual figures by period end, from SEC filings.

$20.60M
Year ended 2025-12-31
$20.61M
Trailing 12 months to 2026-06-30
2023-12-31: $14.42M2024-12-31: $16.96M2025-12-31: $20.60M$20.60M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$20.60M+21.4%2026-03-05, From 2025-01-01
2024-12-31$16.96M+17.6%2026-03-05, From 2024-01-01
2023-12-31$14.42Mn/a2025-03-07, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Profound Medical Corp. (PROF)2025-12-31$20.60M+21.4%
Biotricity Inc. (BTCY)2026-03-31$2.76M+28.2%
Allurion Technologies, Inc. (ALUR)2025-12-31$7.57M-56.4%
Vivos Therapeutics, Inc. (VVOS)2025-12-31$100.0K0.0%
Nephros Inc (NEPH)2025-12-31$1.34M+47.8%
Sonoma Pharmaceuticals, Inc. (SNOA)2026-03-31$2.27M+25.2%
DarioHealth Corp. (DRIO)2025-12-31$13.79M-43.0%
Baird Medical Investment Holdings Ltd (BDMD)2025-12-31$20.13M+226.0%
Nexgel, Inc. (NXGL)2025-12-31$2.0K-97.4%

Compare PROF, BTCY, ALUR, VVOS side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗